The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Novel treatments for inflammatory bowel disease

  • Lee, Hyo Sun (Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Park, Soo-Kyung (Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Park, Dong Il (Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine)
  • Received : 2017.11.28
  • Accepted : 2017.12.04
  • Published : 2018.01.01
⟨ Previous Next ⟩

Abstract

Increased understanding of the immunopathology of inflammatory bowel disease (IBD) has led to the development of targeted therapies and has unlocked a new era in IBD treatment. The development of treatment options aimed at a variety of pathological mechanisms offers new hope for customized therapies. Beyond anti-tumor necrosis factor agents, selective lymphocyte trafficking inhibitors have been proposed as potent drugs for IBD. Among these, vedolizumab has recently been approved for both Crohn's disease and ulcerative colitis. Numerous other agents for IBD treatment are currently under investigation, including Janus kinase inhibitors, anti-mucosal vascular addressin cell adhesion molecule-1 agents, an anti-SMAD7 antisense oligonucleotide, an anti-interleukin-12/23 monoclonal antibody, and a sphingosine-1-phosphate receptor-1 selective agonist. These agents will likely expand the treatment options available for the management of IBD patients in the future. In this review, we discuss the efficacy and safety of novel agents currently under investigation in IBD clinical trials.

Keywords

Acknowledgement

Supported by : National Research Foundation (NRF)

References

  1. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017;390:2769-2778. https://doi.org/10.1016/S0140-6736(17)32448-0
  2. Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res 2016;14:111-119. https://doi.org/10.5217/ir.2016.14.2.111
  3. Singh P, Ananthakrishnan A, Ahuja V. Pivot to Asia: inflammatory bowel disease burden. Intest Res 2017;15:138-141. https://doi.org/10.5217/ir.2017.15.1.138
  4. Lee KM, Lee JM. Crohn's disease in Korea: past, present, and future. Korean J Intern Med 2014;29:558-570. https://doi.org/10.3904/kjim.2014.29.5.558
  5. Burger D, Travis S. Conventional medical management of inflammatory bowel disease. Gastroenterology 2011;140:1827-1837. https://doi.org/10.1053/j.gastro.2011.02.045
  6. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-1549. https://doi.org/10.1016/S0140-6736(02)08512-4
  7. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-265. https://doi.org/10.1053/j.gastro.2011.10.032
  8. Sokol H, Seksik P, Cosnes J. Complications and surgery in the inflammatory bowel diseases biological era. Curr Opin Gastroenterol 2014;30:378-384. https://doi.org/10.1097/MOG.0000000000000078
  9. Kim NH, Jung YS, Moon CM, et al. Long-term clinical outcomes of Korean patient with Crohn's disease following early use of infliximab. Intest Res 2014;12:281-286. https://doi.org/10.5217/ir.2014.12.4.281
  10. Choi CH, Moon W, Kim YS, et al. Second Korean guidelines for the management of ulcerative colitis. Intest Res 2017;15:7-37. https://doi.org/10.5217/ir.2017.15.1.7
  11. Park JJ, Yang SK, Ye BD, et al. Second Korean guidelines for the management of Crohn's disease. Intest Res 2017;15:38-67. https://doi.org/10.5217/ir.2017.15.1.38
  12. Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis 2017;11:769-784. https://doi.org/10.1093/ecco-jcc/jjx009
  13. Gomollon F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: diagnosis and medical management. J Crohns Colitis 2017;11:3-25. https://doi.org/10.1093/ecco-jcc/jjw168
  14. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010;4:355-366. https://doi.org/10.1016/j.crohns.2010.04.004
  15. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011;33:987-995. https://doi.org/10.1111/j.1365-2036.2011.04612.x
  16. Seo HI, Park DI, Kim TO, et al. The effect of infliximab on patients with ulcerative colitis in Korea. Intest Res 2014;12:214-220. https://doi.org/10.5217/ir.2014.12.3.214
  17. Lin WC, Chou JW, Yen HH, et al. Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study. Intest Res 2017;15:487-494. https://doi.org/10.5217/ir.2017.15.4.487
  18. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-$\alpha$ therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 2013;108:1268-1276. https://doi.org/10.1038/ajg.2013.138
  19. Walsh AJ, Weltman M, Burger D, et al. Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2013;7:e449-e456. https://doi.org/10.1016/j.crohns.2013.02.019
  20. Lee JW, Choi CH, Park JH, et al. Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Intest Res 2016;14:146-151. https://doi.org/10.5217/ir.2016.14.2.146
  21. Chung KB, Lee EY, Im JP, Han SK, Yim JJ. Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-$\alpha$ inhibitor. Korean J Intern Med 2013;28:174-179. https://doi.org/10.3904/kjim.2013.28.2.174
  22. Lobaton T, Vermeire S, Van Assche G, Rutgeerts P. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2014;39:579-594. https://doi.org/10.1111/apt.12639
  23. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-1925. https://doi.org/10.1056/NEJMoa043335
  24. Villablanca EJ, Cassani B, von Andrian UH, Mora JR. Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory bowel diseases. Gastroenterology 2011;140:1776-1784. https://doi.org/10.1053/j.gastro.2011.02.015
  25. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-1880. https://doi.org/10.1056/NEJMoa1107829
  26. Lowenberg M, D'Haens G. Next-generation therapeutics for IBD. Curr Gastroenterol Rep 2015;17:21. https://doi.org/10.1007/s11894-015-0444-2
  27. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710. https://doi.org/10.1056/NEJMoa1215734
  28. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-721. https://doi.org/10.1056/NEJMoa1215739
  29. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014;147:618-627. https://doi.org/10.1053/j.gastro.2014.05.008
  30. Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2017;66:839-851. https://doi.org/10.1136/gutjnl-2015-311079
  31. Vermeire S, Loftus EV Jr, Colombel JF, et al. Long-term efficacy of vedolizumab for Crohn's disease. J Crohns Colitis 2017;11:412-424.
  32. Loftus EV Jr, Colombel JF, Feagan BG, et al. Long-term efficacy of vedolizumab for ulcerative colitis. J Crohns Colitis 2017;11:400-411.
  33. Cepek KL, Parker CM, Madara JL, Brenner MB. Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells. J Immunol 1993;150(8 Pt 1):3459-3470.
  34. Vermeire S, O'Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 2014;384:309-318. https://doi.org/10.1016/S0140-6736(14)60661-9
  35. Vermeire S, Ghosh S, Panes J, et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut 2011;60:1068-1075. https://doi.org/10.1136/gut.2010.226548
  36. Vermeire S, Sandborn WJ, Danese S, et al. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2017;390:135-144. https://doi.org/10.1016/S0140-6736(17)30930-3
  37. D'Haens G, Lee S, Tarabar D, et al. OP022 Anti-MAd-CAM-1 antibody (PF-00547659) for active refractory Crohn's disease: results of the OPERA study. 10th Congress of European Crohn's and Colitis Organisation (ECCO); 2015 Feb 18-21; Barcelona, ES. Vienna (AT): ECCO, 2015: S14.
  38. Lundquist LM, Cole SW, Sikes ML. Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis. World J Orthop 2014;5:504-511. https://doi.org/10.5312/wjo.v5.i4.504
  39. Vijayakrishnan L, Venkataramanan R, Gulati P. Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends Pharmacol Sci 2011;32:25-34. https://doi.org/10.1016/j.tips.2010.10.004
  40. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367:616-624. https://doi.org/10.1056/NEJMoa1112168
  41. Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med 2016;374:1754-1762. https://doi.org/10.1056/NEJMoa1513248
  42. D'Haens GR, Panaccione R, Higgins P, et al. 856 Efficacy and safety of oral tofacitinib for maintenance therapy in patients with moderate to severe Crohn's disease: results of a phase 2B randomized placebo-controlled trial. Gastroenterology 2016;150(4 Suppl 1):S183.
  43. Sandborn WJ, Ghosh S, Panes J, et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014;12:1485-1493. https://doi.org/10.1016/j.cgh.2014.01.029
  44. Panes J, Sandborn W, Schreiber S, et al. 855 Efficacy and safety of tofacitinib for oral induction therapy in patients with moderate to severe Crohn's disease: results of a phase 2B randomized placebo-controlled trial. Gastroenterology 2016;150(4 Suppl 1):S182-S183.
  45. Di Sabatino A, Jackson CL, Pickard KM, et al. Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut 2009;58:777-789. https://doi.org/10.1136/gut.2008.149096
  46. Marafini I, Zorzi F, Codazza S, Pallone F, Monteleone G. TGF-beta signaling manipulation as potential therapy for IBD. Curr Drug Targets 2013;14:1400-1404. https://doi.org/10.2174/13894501113149990157
  47. Kennedy BW. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med 2015;372:2461. https://doi.org/10.1056/NEJMc1504845
  48. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-1674. https://doi.org/10.1016/S0140-6736(08)60725-4
  49. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-1684. https://doi.org/10.1016/S0140-6736(08)60726-6
  50. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;135:1130-1141. https://doi.org/10.1053/j.gastro.2008.07.014
  51. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012;367:1519-1528. https://doi.org/10.1056/NEJMoa1203572
  52. Hibi T, Imai Y, Murata Y, Matsushima N, Zheng R, Gasink C. Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies. Intest Res 2017;15:475-486. https://doi.org/10.5217/ir.2017.15.4.475
  53. Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem 2004;92:913-922. https://doi.org/10.1002/jcb.20127
  54. Narula N, Rubin DT, Sands BE. Novel therapies in inflammatory bowel disease: an evaluation of the evidence. Am J Gastroenterol Suppl 2016;3:38-44. https://doi.org/10.1038/ajgsup.2016.19

Cited by

  1. Epidemiology, disease burden, and treatment challenges of ulcerative colitis in Africa and the Middle East vol.12, pp.9, 2018, https://doi.org/10.1080/17474124.2018.1503052
  2. Impact of Modern Drug Therapy on Surgery: Ulcerative Colitis vol.34, pp.6, 2018, https://doi.org/10.1159/000493492
  3. Organometallic Compounds and Metal Complexes in Current and Future Treatments of Inflammatory Bowel Disease and Colorectal Cancer-a Critical Review vol.9, pp.9, 2019, https://doi.org/10.3390/biom9090398
  4. Experimental Evaluation of the Impact of Gadolinium Orthovanadate GdVO4:Eu3+ Nanoparticles on the Carrageenan-Induced Intestinal Inflammation vol.63, pp.1, 2018, https://doi.org/10.14712/18059694.2020.11
  5. In vivo Imaging Technologies to Monitor the Immune System vol.11, pp.None, 2018, https://doi.org/10.3389/fimmu.2020.01067
  6. Challenges and opportunities for IBD drug development: from early stage to regulatory approval vol.69, pp.7, 2020, https://doi.org/10.1136/gutjnl-2019-320542
  7. Inflammatory bowel disease: tri-directional relationship between microbiota, immune system and intestinal epithelium vol.47, pp.2, 2018, https://doi.org/10.1080/1040841x.2021.1876631